



Scientific Program

Friday, May 17th 2024

10:00 -10:15 **Congress Opening**

10:15 - 12:30 **Plenary Session 1: Emerging trends in cancer-associated thrombosis (Part I)**

Chairs: *Benjamin Brenner (Israel), Paolo Simioni (Italy)*

Endothelial cell dysfunction in cancer: a modulator of CAT and metastasis?

Jamie O'Sullivan (Ireland)

Artificial Intelligence in CAT

Rushad Patell (USA)

The gut microbiome in cancer and thrombosis

Christoph Reinhardt (Germany)

Stroke in patients with cancer

Deborah Siegal (Canada)

Selected Abstract

OC01_IMMUNE CHECKPOINT BLOCKADE PROMOTES THROMBOSIS VIA T-CELL AND NEUTROPHIL ACTIVATION, AND TUMOR-CELL ASSOCIATED TISSUE FACTOR (TF) IN A MURINE MODEL OF COLORECTAL CANCER
Y Shim, B Sharma, Y Hisada, N Mackman, J Palumbo, M Diaz-Montero, A Khorana, Keith McCrae (USA)

OC02_NAVIGATING THE INTERPLAY OF CANCER, HEMOSTASIS, AND THROMBOSIS: INVESTIGATING TISSUE FACTOR IN COLORECTAL CANCER (CALGB/SWOG 80405)
Sandra Algaze, Y. Yang, J. Millstein, F. Battaglin, S. Soni, P. Mittal, K. Ashouri, A. Wong, P. Jayachandran, H. Arai, J. H. Lo, W. Zhang, L. Torres-gonzalez, H. Liebman, H. J. Lenz (USA)

12:30 -13:30 **Debate: Do we need more complex and specific RAMs for CAT?**

Chairs: *Paolo Prandoni (Italy), Mario Mandalà (Italy)*

YES: *Andres Munoz-Martin (Spain)*

NO: *Ingrid Pabinger (Austria)*

13:30 – 14:30 **Lunch Sessions**

14:30 – 15:00 **Coffee**



15:00 – 17:15 **Plenary Session 2: Emerging trends in cancer-associated thrombosis (Part II)**

Chairs: *Laurent Bertoletti (France), Francesco Dentali (Italy)*

Trends and Updates on the Epidemiology of Cancer-Associated Thrombosis

Ang Li (USA)

Cancer immunotherapy in CAT

Claudine Graf (Germany)

Bleeding and thrombosis during CAR-T therapy

Elena Rossi (Italy)

Location of metastasis and complications of anticoagulant treatment

Maria Barca-Hernando (Spain)

Selected Abstracts

OC03_ PREDICTION OF CLINICALLY SIGNIFICANT BLEEDING IN PATIENTS ANTICOAGULATED FOR CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: VALIDATION OF THE B-CAT SCORE IN A COHORT OF PATIENTS FROM THE TESEO STUDY

Javier López Robles, M. Sánchez Cánovas, C. Iglesias, L. Ortega Morán, L. Sánchez Togneri, J. Rubio, I. Fernández Pérez, M. García De Herreros, I. García Escobar, R. Porta, E. Brozos, M. Carmona Campos, E. Martínez De Castro, H. Olivares, T. Quintanar, S. García Adrián, M. Covela Rúa, A. Carmona Bayonas, P. Jiménez Fonseca, Aj. Muñoz Martín, On Behalf of Teseo Registry Investigators (Spain)

OC04_ TISSUE FACTOR PATHWAY-RELATED BIOMARKERS IN PANCREATIC CANCER: PLASMA LEVELS OF ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX MAY PREDICT VENOUS THROMBOEMBOLISM

Elena Campello, M. Spizzo, A. Castagna, F. T. M. Bosch, F. I. Mulder, N. Van Es, S. Gavasso, P. Pattini, A. Rousseau, P. Van Dreden, S. Friso, H. R. Büller, P. Simioni, N. Martinelli (Italy, The Netherlands, France)

17:15 - 17:45 Coffee Break

17:45 – 18:45 **Plenary Lecture: 8th Simon Karparkin Memorial Lecture**

The Conference Chairs

Introduction to Lecture: *Alok A. Khorana (USA)*

VTE treatment in patients with cancer: Reflections on an evolving landscape

Agnes Y.Y. Lee (Canada)



Saturday, May 18th 2024

8:30 – 10:45 Plenary Session 3: Anticoagulation in hematological cancer patients

Chairs: *Roberto Santi (Italy), Giancarlo Castaman (Italy)*

VTE and mortality in patients with hematological malignancies

Kristen Sanfilippo (USA)

Management of CAT in thrombocytopenia: the uncertain balance between risks and benefits of platelet transfusion to support anticoagulation

Simon J. Stanworth (UK)

Pharmacological approach to increase platelet count: from ITP to chemotherapy-induced thrombocytopenia

Monica Carpenedo (Italy)

Selected Abstracts

OC05_ THE RISK OF THROMBOEMBOLIC RECURRENCE OUTWEIGHS THE RISK OF MAJOR BLEEDING IN CANCER PATIENTS TREATED WITH TINZAPARIN, EVEN IN PATIENTS WITH FRAGILITY CRITERIA. META-ANALYSIS OF PROSPECTIVE STUDIES INVOLVING 1413 INDIVIDUAL PATIENTS' DATA

Isabelle Mahé, C Chapelle, G. Poenou, L. Jara-palomares, A. Y. Y. Lee, O. Sanchez, G. Meyer, P. Girard, S. Laporte (France, Spain, Canada)

OC06_ RAPID EXCLUSION OF CLINICALLY RELEVANT PLASMA LEVELS OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS USING THE DOAC DIPSTICK IN VARIOUS INDICATIONS

Job Harenberg, W. Ageno, C. Becattini, J. Douxfils, A. Falanga, S. Hetjens, M. Marchetti, J. Vassart, F. Violi, C. Weiss, J. Weitz, On Behalf of The Doac Poct Working Group (Germany, Italy, Canada)

10:45 – 11:15 Coffee break



11:15 – 13:30 **Plenary Session 4: Exploring the relationship between hemostasis and cancer:**

New insights

Chairs: *Erica De Candia (Italy), Hugo ten Cate (The Netherlands)*

Platelets: A weapon against cancer

Paolo Gresele (Italy)

FXa inhibitors in cancer progression

Andrea Alimonti (Switzerland)

Coagulome and tumor microenvironment

Janusz Rak (Canada)

Crosstalk between NETs and tumor progression

Laurence Panicot-Dubois (France)

Selected Abstracts

OC07_ INVESTIGATING A PROPOSED ANTI-CANCER IMMUNITY EFFECT OF RIVAROXABAN IN BREAST CANCER.

U. Singh, J. Castle, S. Pritchard, R. Hunt, J. R. Harvey, C. Holcombe, A. Volleamere, B. Hogan, R. Vinayagam, P. G. Roy, M. Bramley, J. Kokan, C. Palmieri, K. Cox, J. Thachil, R. Jackson, A. Marshall, L. Turner, N. J. Bundred, Cliona C. Kirwan (UK)

OC08_ TUMOR PLATELET TRANSCRIPTOME CHANGES AFFECTED BY MICRO METASTASIS

Carina Dinis Santos Rodrigues, J. Braun, S. Schubert, F. Marini, C. Graf, B. Schrörs, W. Ruf (Germany, USA)

13:30 – 14:30 Lunch

14:30 – 15:00 Coffee

15:00 – 17:00 **Poster Discussion Sessions (see pages 8-16)**

Poster Session 1: Biomarkers/Hypercoagulability I

Chair: Norma Maugeri (Italy)

Poster Session 2: Thrombohemorrhagic complications

Chair: Elena Rossi (Italy)

Poster Session 3: Epidemiology

Chair: Marina Marchetti (Italy)

Poster Session 4: Thromboprophylaxis in cancer

Chair: Arina J. ten Cate (The Netherlands)



Poster Session 5: Treatment of thrombosis in cancer

Chair: Elvira Grandone (Italy)

Poster Session 6: Hemostatic proteins and cancer biology

Chair: Giulia Taraboletti (Italy)

Poster Session 7: Therapeutic challenges

Chair: Mariasanta Napolitano (Italy)

Poster Session 8: Biomarkers/Hypercoagulability II

Chair: Francesca Schieppati (Italy)

17:00 – 18:15 Interactive session: Spotlight on prevention of VTE in cancer patients

Chair: *Ajay K. Kakkar (UK)*

A case of thrombosis in medical patient

Walter Ageno (Italy)

A case of thrombosis in surgical patient

Giancarlo Agnelli (Italy)

A case of thrombosis during anti-cancer drug treatment

Marina Elena Cazzaniga (Italy)

Discussant: *Anna Falanga (Italy), G. Lyman (USA)*

18:15 – 19:00 Special "Noble" Session

Chairs: *Anna Falanga (Italy), Caterina Rizzi (Italy)*

Patient and Public Involvement in CAT Research: Necessary or glorified tokenism?

Simon Noble (UK)



Sunday, May 19th 2024

8:30 – 10:15 **Plenary Session 5: Past, present, and future of CAT - A Round Table Discussion**

Chairs: *Elvira Grandone (Italy), Alok A. Khorana (USA)*

New drugs, old problems: Immune checkpoint inhibitors and CAT

Alok A. Khorana (USA)

Real-world Outcomes Data for DOAC vs LMWH vs other Anticoagulants: Promises and Pitfalls

Nicole Kuderer (USA)

FXI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

Marcello Di Nisio (Italy)

General Discussion

10:15 – 11.45 **Plenary session 6: Novel biomarkers for predicting clinical outcomes in cancer patients**

Chairs: *Marina Marchetti (Italy), Andrea Remuzzi (Italy)*

Proteomics prediction of CAT and mechanistic insights

Jeffrey Zwicker (USA)

Age-related clonal hemopoiesis and thrombosis

Liran I. Shlush (Israel)

Machine Learning for the prediction of CAT

Simon Mantha (USA)

Selected Abstracts

OC09_ GROWTH DIFFERENTIATION FACTOR-15 IS ASSOCIATED WITH RISK OF MAJOR BLEEDING IN CANCER PATIENTS WITHOUT ANTICOAGULATION: RESULTS FROM A PROSPECTIVE COHORT STUDY

Cornelia Englisch, S. Nopp, I. Pabinger, F. Moik, D. Steiner, A. M. Starzer, M. Fritzer-szekeres, M. Preusser, A. S. Berghoff, C. Ay (Austria)

OC010_ PREDICTIVE VALUE OF ACTIVATED FXI-ANTITHROMBIN COMPLEX IN CANCER ASSOCIATED THROMBOSIS (CAT): A PROSPECTIVE COHORT STUDY IN LUNG CANCER PATIENTS

Patricia Gomez-Rosas, M. Marchetti, M. Nagy, H. M. H. Spronk, L. Russo, C. Verzeroli, S. Gamba, C. J. Tartari, S. Bolognini, C. Ticozzi, F. Schieppati, R. Sarmiento, F. De Braud, G. Masci, C. Tondini, F. Petrelli, F. Giuliani, A. D'alessio, A. Santoro, G. Gasparini, R. Labianca, H. T. Cate, A. Falanga, On Behalf Of The Hypercan Investigators (Italy)

11:45 - 12:45 **Lunch**



12:45 – 14:35 Plenary Session 7: Anticoagulation in cancer patients

Chairs: Anna Falanga (Italy), Roberto Labianca (Italy)

Risk of recurrent VTE in cancer patients after discontinuation of anticoagulant therapy

Gary E Raskob (USA)

Extended antithrombotic prophylaxis after cancer surgery

Cecilia Becattini (Italy)

Trends in the management of pediatric and adolescent patients with cancer-associated VTE

Gili Kenet (Israel)

Selected Abstracts

OC11_MANAGING A CANCER-ASSOCIATED THROMBOSIS CLINIC - OPPORTUNITIES AND CHALLENGES.

Shahid Gilani, D. Chandra (United Kingdom)

OC12_PROGNOSTIC FACTORS ASSOCIATED WITH RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS

F Khan, T Tritschler, Ce Marx, V Lanting, B Rochweg, A Tran, S Fernando, D Lorenzetti, H Wunsch, J Holodinsky, K Fiest, Ht Stelfox, A Delluc, D Fergusson, G Le Gal, P Wells, N Van Es, J M Connors, Marc Carrier (Canada, USA, Switzerland, The Netherlands)

14:35 – 14:40 Concluding Remarks



POSTER DISCUSSION SESSIONS

Poster Session I: Biomarkers/hypercoagulability I

Chair: Norma Maugeri (Italy)

- | | |
|-------|--|
| PO-01 | <p>ALTERED WHOLE BLOOD THROMBIN GENERATION AND HYPERRESPONSIVE PLATELETS ASSOCIATE WITH THROMBOEMBOLIC EVENTS IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA</p> <p>R. A. L. Willems, J. Konings, D. Huskens, H. Ten Cate, J. De Vos-geelen, B. De Laat, M. Roest</p> |
| PO-02 | <p>THROMBO-HEMORRHAGIC EVENTS AND TISSUE FACTOR EXPRESSION IN NEWLY DIAGNOSED PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA RECEIVING INDUCTION THERAPY</p> <p>F. Schieppati, L. Russo, C. J. Tartari, T. Barbui, E. Di Bona, M. Marchetti, A. Falanga</p> |
| PO-03 | <p>PLASMA MARKERS OF HEMOSTATIC ACTIVATION AND FIBRINOLYSIS IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER BEFORE AND AFTER SECONDARY HORMONAL THERAPY AND ANTI-PSMA RADIOIMMUNOTHERAPY</p> <p>Z. Davidson, C. Thomas, D. M. Nanus, A. Patel, N. Adra, Y. Zakharia, J. Osborne, N. H. Bander, S. T. Tagawa</p> |
| PO-04 | <p>ALTERED PLASMIN GENERATION IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA</p> <p>R. Willems, I. De Simone, C. Biesmans, J. Konings, S. Tufaha, H. Ten Cate, B. De Laat, M. Roest, D. Huskens, J. De Vos-geelen</p> |
| PO-05 | <p>AN MRI RADIOMICS APPROACH TO PREDICT THE HYPERCOAGULABLE STATUS OF GLIOMAS</p> <p>Z. Saidak, A. Laville, S. Soudet, M. A. Sevestre, J. M. Constans, A. Galmiche</p> |
| PO-06 | <p>ANTIPHOSPHOLIPID ANTIBODIES IN WOMEN WITH ENDOMETRIAL AND CERVICAL CANCER</p> <p>J. Khizroeva, A. Makatsariya, V. Bitsadze, A. Solopova, A. Vorobev, I. Elalamy, M. Tretyakova, N. Makatsariya, T. Mashkova, Z. Aslanova, E. Kudryavtseva, I. Dikaeva, E. Efendieva</p> |
| PO-07 | <p>RAPID AND EFFECTIVE ISOLATION OF HUMAN PLATELETS FROM WHOLE BLOOD: MAXIMIZING PURITY FOR EVALUATING PROTEOMICS METHODS IN CLINICAL STUDIES FOR CANCER PATIENTS</p> <p>V. Markhus, D. Goplen, F. Selheim</p> |
| PO-08 | <p>FACTOR VIII C IMPROVES PREDICTION OF VTE BY THE THROMBOGYN SCORE</p> <p>Elzahra Ibrahim, Mark P Ward, Ciara Mc Goldrick, Delish Ramesh, Sharon O' Toole, Feras Abu Saadeh, Lucy A Norris</p> |



Poster Session II: Thrombohemorrhagic complications

Chair: Elena Rossi (Italy)

- PO-09 ASSOCIATION BETWEEN ANTICOAGULATION-RELATED BLEEDING AND MORTALITY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM
T-F. Wang, S. Luo, M. Schoen, A. Afzal, S-h. Chang, K. Carson, K. Sanfilippo
- PO-10 ASSOCIATION BETWEEN ANTICOAGULATION-RELATED BLEEDING AND MORTALITY IN PERSONS WITH SOLID TUMORS
A. Mahmoud, S. Luo, M. Schoen, B. Gage, A. Afzal, S. Chang, K. Carson, K. Sanfilippo
- PO-11 CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: A CASE OF A POSSIBLE RESISTANCE TO DOAC
S. Kozhukhov, N. Dovganych
- PO-12 RISK OF RETHROMBOSIS AND MAJOR BLEEDING IN WOMEN WITH CANCER INCLUDED IN THE TESEO-SEOM REGISTRY
S. García Adrián, L. Ortega Morán, A. Carmona-bayonas, C. Iglesias-pérez, E. M. Brozos Vázquez, E. Martínez De Castro, C. Díaz Pedroche, F. Neria, T. Quintanar Verduguez, M. Covela Rúa, P. Jiménez-fonseca, M. Sánchez Cánovas, J. A. Santiago Crespo, M. Biosca Gómez De Tejada, F. J. Pelegrin Mateo, B. Obispo Portero, M. Lobo De Mena, A. J. Muñoz Martín, On Behalf Of Teseo Registry Investigators
- PO-13 RISK OF CAR T-CELL THERAPY-RELATED THROMBOSIS AND BLEEDING: PRELIMINARY RESULTS OF THE MULTICENTER 'FOLLOW THAT CAR' REGISTRY
A. K. Ko, P. N. J. Mutsaers, F. W. G. Leebeek, M. N. Lauw
- PO-14 ESTIMATING RISK OF BLEEDING AND THROMBOSIS FOR THROMBOCYTOPENIA IN CANCER-ASSOCIATED SPLANCHNIC VEIN THROMBOSIS: A TIME-VARYING ANALYSIS
K. Barnum, M. Andersen, M. Fernandez, L. Dodge, C. Hsu, J. Berry, J. Zwicker, R. Patell
- PO-15 THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH NIVOLUMAB AND IPILIMUMAB IMMUNOTHERAPY IN METASTATIC MELANOMA: A CASE REPORT
J. Depaus, E. Collinge, A. Sonet
- PO-16 FURTHER PROOF THAT THE OTTAWA SCORE FAILS TO PREDICT RECURRENT VTE IN CANCER PATIENTS. META-ANALYSIS OF INDIVIDUAL PATIENT DATA
C. Chapelle, I. Mahé, G. Poenou, L. Jara-palomares, A. Y. Y. Lee, O. Sanchez, G. Meyer, P. Girard, S. Laporte
- PO-17 USUAL-SITE VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER-ASSOCIATED SPLANCHNIC VEIN THROMBOSIS
K. Barnum, M. Andersen, M. Fernandez, L. Dodge, C. Hsu, J. Berry, J. Zwicker, R. Patell
- PO-18 DEEP VEIN THROMBOSIS AS AN INITIAL SYMPTOM OF PROSTATAE CANCER: A CASE REPORT
M. Shorova, N. Jovanova, B. Panev, M. Stoileva, R. Grubovik-ratsvorcev, E. Petkovik, D. Stambolieva



Poster Session III: Epidemiology

Chair: Marina Marchetti (Italy)

- PO-19 PROGNOSTIC VALUE OF HULL SCORE 0 VERSUS SUBSEGMENTAL UNSUSPECTED PULMONARY EMBOLISM IN CANCER PATIENTS: A COMPARATIVE ANALYSIS
F. Haque, J. Ryde, L. Broughton, A. Stephens, A. Pillai, S. Mirza, V. Brown, G. Averya, G. Bozas, A. Maraveyas
- PO-20 VENOUS THROMBOEMBOLISM AND RISK OF CANCER IN PATIENTS WITH STROKE: A POPULATION-BASED COHORT STUDY
O. Rosenkrantz, D. Nagy, E. Horváth-puhó, C. H. Fuglsang, H. T. Sørensen
- PO-21 VENOUS THROMBOEMBOLISM AND RISK OF CANCER IN PATIENTS WITH A HISTORY OF MIGRAINE: A POPULATION-BASED COHORT STUDY
O. Rosenkrantz, D. Nagy, E. Horváth-Puhó, C. H. Fuglsang, H.T. Sørensen
- PO-22 SENSITIVITY AND POSITIVE PREDICTIVE VALUE OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM DIAGNOSES IN THE DANISH NATIONAL PATIENT REGISTER
T.F. Overvad, M.T. Severinsen, S.P. Johnsen, S.S. Madsen, K. Kannik, L. G. Stenfeldt, T.B. Larsen, P.B. Nielsen
- PO-23 VENOUS THROMBOEMBOLISM IN CANCER PATIENTS AND SELF-RATED HEALTH: A CROSS-SECTIONAL STUDY
J. Viuff, S. Korsgaard, C. Nielsen, F. Kristensen, H. Sørensen
- PO-24 POLY (ADP-RIBOSE) POLYMERASE INHIBITORS (PARPI) – ASSOCIATED THROMBOSIS IN PATIENTS WITH OVARIAN CANCER: A STUDY OF THE SPANISH SOCIETY OF MEDICAL ONCOLOGY (SEOM) THROMBOSIS AND CANCER GROUP
J. López Robles, M. Sánchez Cánovas, Fj. García Verdejo, D. Cacho Lavin, C. Díaz Pedroche, A. Garrido Fernández, E.Coma Salvans, T. Quintanar, C. Salvador Coloma, D. Fernández Garay, Jd. Cumplido, Ai. Ferrer Pérez, A. Carbó Bagué, J. Teigell, AJ. Muñoz Martín
- PO-25 IMPACT OF THROMBOEMBOLIC EVENTS ACROSS THE SPAN OF BREAST CANCER SURVIVORSHIP: DATA FROM A LARGE OBSERVATIONAL STUDY ON LONG-TERM BREAST CANCER SURVIVORS
J. Illarramendi, J. I. Arraras, G. Asin, A. Manterola, E. Salgado, S. De La Cruz, E. Gomez, M. V. Aznar, J. Coll, M. J. Paloma, M. Rodriguez-calvillo, J. J. Illarramendi, M. Redondo
- PO-26 VENOUS THROMBOEMBOLISM AND RISK OF CANCER IN PATIENTS WITH ATOPIC DERMATITIS
S. T. Sørensen, C. H. F. Nielsen, D. Nagy, E. Horváth-Puhó
- PO-27 EPIDEMIOLOGIC STUDY OF PATIENTS WITH THROMBOTIC EVENTS REFERRED TO A TERTIARY HOSPITAL IN SOUTHERN IRAN
Ahmad Akbari, Sezaneh Haghpanah, Hamide Barzegar, Amin Shahsavani, Abdolreza Afrasiabi, Shirin Parand, Mehran Karimi



- PO-28 RATES OF VENOUS THROMBOEMBOLISM DURING NEOADJUVANT CHEMOTHERAPY FOR OVARIAN CANCER: A NATIONAL STUDY OF UK GYNAECOLOGICAL CANCER CENTRES
S. Oxley, M. Sideris, M. Brincat, A. Pandya, G. Owens, N. Gomes, N. Ryan, V. Braden, A. Durden, N. Ryan, K. Baxter, J. Prince, N. Zamesa, S. Bryan, S. Tanna, F. Kokka, J. Waters, J. Lowe-Zinola, A. McCormick, B. Johnston, C. Nott, S. Ahmed, D. Blake, J. Dilley, S. Dobbs, M. Lockley, A. Olaitan, M. Thomas

Poster Session IV: Thromboprophylaxis in cancer

Chair: Arina J. ten Cate (The Netherlands)

- PO-29 ELECTRONIC HEALTH RECORD (EHR) INTEGRATION OF THROMBOEMBOLISM RISK STRATIFICATION MODEL IN PATIENTS WITH CANCER
A. Li, D. Guffey, R. Bandy, S. Ma, O. Jafari, E. Zhou, M. Ranjan, K. Martin, A. Jotwani
- PO-30 APIXABAN THROMBOPROPHYLAXIS IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING CHEMOTHERAPY: A COHORT STUDY
Y. Tan, S. Mariathasan, Z Sayar, J. Sive, A. Tailor, M. Thomas
- PO-31 TINZAPARIN PROPHYLAXIS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (PROTINCOL)
A. Muñoz Martín, J. De La Camara, I. García Escobar, R C. Álvarez Llosa, P. Gonzalez Villarroel, D. Fernández Garay, M. Pampols, M. Guillot, F J. Pelegrín Mateo, E. Jiménez, J. Sastre, E. Martínez De Castro, E. Coma, L. París Bouzas, A I. Ferrer Pérez, Y. De Miguel, E. Mompradé Olivé, L. Robles Díaz, J M Soria, M. Salgado
- PO-32 COMPARATIVE ANALYSIS OF RISK PREDICTION SCORES INCLUDING ALL TYPE OF CANCER ASSOCIATED THROMBOSIS.
I. González, B. Lobato, M. Ruiz, I. Ávila, M. Salgado, V. Pachón, J. Martinez, E. Martinez, A. Ferrer, J. Rubio, I. Garcia, I. Fernandez, T. Quintanar, C. Font, J. Soto, L. Ortega, Jm. Soria, A. Muñoz
- PO-33 DIRECT ORAL ANTICOAGULANTS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER CANCER SURGERY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
G. N. Pititto, G. Maraziti, A. Squizzato, A. Fiaccadori, C. Becattini
- PO-34 BARRIERS TO VTE PREVENTION IN AMBULATORY ONCOLOGY PRACTICE: A CLINICIAN-BASED SURVEY
M. Ranjan, A. Jotwani, A. Li, K. Martin
- PO-35 EXPLORING THE IMPACT OF KRAS MUTATION TYPE ON THE THROMBOTIC RISK
M. Seladas, R. Escalera, J. Mendes, J. Gramaça, I. Guerreiro
- PO-36 ANTITHROMBOTIC AND ANTI-LEUKENIC EFFECTS OF RICINUS COMMUNIS IN BENZENE-INDUCED LEUKEMIC WISTAR RATS
A.Kosamat, A. Olabisi, I. Ajayi
- PO-37 CANCER ASSOCIATED THROMBOSIS (CAT): OPTIMIZING VTE PREVENTION AND IMPROVING PATIENT CARE EXPERIENCE
N. Khargie, S. Jenkins, E. Yeo, C. Kurtin



- PO-38 CANCER ASSOCIATED THROMBOSIS: SURVEYING PATIENTS' AWARENESS AND EDUCATION NEEDS
I. Tataka, A. Li, A. Parks, J. Schaefer, A. Gutierrez Bernal, S. Chaturvedi, A. Mahajan, J. May, L. Tefera,
B. Roberston, L. Lake, D. Angelini, R. Patell

Poster Session V: Treatment of thrombosis in cancer

Chair: Elvira Grandone (Italy)

- PO-39 USE OF TINZAPARIN IN THE TREATMENT OF PICC-RELATED THROMBOSIS IN CANCER PATIENTS
I. De La Haba, E. Coma, C. Tudela, A. Benito, R. Arcega, M. Merino, E. Colomé
- PO-40 DIRECT ORAL ANTICOAGULANTS ARE COMPARABLE TO LOW MOLECULAR WEIGHT HEPARIN AT
REDUCING PROCOAGULANT EXTRACELLULAR VESICLES AND PROTEOMIC SIGNATURES FOR THE
TREATMENT OF CANCER ASSOCIATED THROMBOSIS
H. Macleod, N. Copt, D. Doherty, R. Power, N. Ryan, K. Saeed, E. O'rourke, S. Macleod, R. Faryal, L.
Weiss, S. Kelliher, B. Kevane, F. Ní Áinle, P. B Maguire
- PO-41 ANTITHROMBOTIC THERAPY DECISION-MAKING IN ADVANCED CANCER: KEY FACILITATORS AND
BARRIERS
A. A. Højen, E. Baddeley, M. Edwards, S. Sivell, K. Lifford, C. Font, V. M. Arfuch, N. Coma-auli, I. Mahe,
H. Enggaard, M. Søgaaard, F. A. Klok, S. Noble
- PO-42 EFFECTS OF TINZAPARIN ON THE PRESENCE OF RESIDUAL THROMBUS IN PATIENTS WITH CANCER-
ASSOCIATED THROMBOSIS
C. Rosa-Linares, M. Barca-Hernando, S. Lopez-Ruz, V. Garcia-Garcia, L. Jara-Palomares
- PO-43 A SINGLE-CENTER EXPERIENCE WITH THE USE OF TINZAPARIN FOR THE TREATMENT OF VENOUS
THROMBOEMBOLIC EVENTS IN BREAST CANCER PATIENTS ON THERAPY WITH TARGETED DRUG
AGENTS
J. Illarramendi, J.I. Arraras, L. Teijeira, E. Salgado, S. De La Cruz, E. Gómez, M. V. Aznar, J. Coll, M.
Martínez-Calvillo, M. J. Paloma, M. Redondo, J. J. Illarramendi
- PO-44 TREATMENT OF CANCER ASSOCIATED VENOUS THROMBOSIS WITH EDOXABAN IN PATIENTS
RECEIVING CONCOMITANT ENZALUTAMIDE
T. Groves, N. Pease, S. Noble, L. Green, R. Alikhan
- PO-45 CHEMOTHERAPY ASSOCIATED CEREBRAL VENOUS SINUS THROMBOSIS(CVST)-EXPERIENCE FROM A
TERTIARY CANCER CENTRE
S. Sawant, A. Daddi, G. Goel
- PO-46 DURATION OF ANTICOAGULATION IN CANCER ASSOCIATED THROMBOSIS WHAT IS IDEAL
T. S. Hund, Y. R. Tan, N. Pandit
- PO-47 WHAT IS THE IDEAL ANTICOAGULANT?
K. Karthigayan, Z. Qi, N. Pandit



- PO-48 A 44 KILOS UTERINE FIBROID RESECTION COMPLICATED BY EXTENDED VENOUS THROMBOEMBOLISM NOT SOLVED BY FULL DOSE EDOXABAN. A CLINICAL CASE.
A. M. Fioretti, T. Leopizzi, D. La Forgia, R. De Luca, D. Oreste, S. Strippoli, P. Pizzutilo, P. Scicchitano, G. Cormio, N. D. Brunetti, C. G. Tocchetti, S. Oliva

Poster Session VI: Hemostatic proteins and cancer biology

Chair: Giulia Taraboletti (Italy)

- PO-49 ANTI-PROLIFERATIVE, ANTI-ANGIOGENIC AND ANTI-INVASIVE EFFECT OF ANTITHROMBIN IN GLIOBLASTOMA MULTIFORME
J. Peñas-Martínez, D. Zaragoza-Huesca, S. Espín, C. Martínez, R. González-Conejero, M. L. Lozano, V. Vicente, I. Martínez
- PO-50 RIVAROXABAN COMPARED TO NO TREATMENT IN EARLY BREAST CANCER PATIENTS (THE TIP TRIAL, EUDRACT 2014-004909-33): EFFECT ON EPCAM SERUM CONCENTRATIONS AS A SURROGATE FOR CIRCULATING TUMOUR CELLS (CTCS)
J. Castle, S. Pritchard, R. Hunt, J. R. Harvey, C. Holcombe, A. Volleamere, B. Hogan, R. Vinayagam, P. G. Roy, M. Bramley, J. Kokan, C. Palmieri, K. Cox, J. Thachil, R. Jackson, A. Marshall, L. Turner, N. J. Bundred, C.C. Kirwan
- PO-51 CHARACTERISATION OF PROCOAGULANT FIBROBLASTS IN THE EARLY BREAST CANCER MICROENVIRONMENT THROUGH EX VIVO CULTURE
H. Ogunlayi, J. Castle, R. Clarke, S. Pritchard, S. Wahballa, Y. Y. Lim, C. C. Kirwan
- PO-52 CANCER ASSOCIATED THROMBOSIS ALTERS NEUTROPHILS TO PROMOTE PANCREATIC DUCTAL ADENOCARCINOMA PROGRESSION
Asha Thomas, Yuexin Li, Kenneth Kalikasingh, Elton Tong, David Prots, Annmarie Madera, Stephanie Lapping, Lalitha Nayak
- PO-53 GLUCOCORTICOIDS AS TRANSCRIPTIONAL REGULATORS OF THE TUMOR COAGULOME OF ORAL SQUAMOUS CELL CARCINOMAS
F. Racine, C. Louandre, C. Godin, B. Chatelain, Z. Saidak, A. Galmiche
- PO-54 DESCRIPTION OF CLINICAL AND MOLECULAR FEATURES IN CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM
M. Roca-Herrera, S. Serradell, B. Alonso, S. Eremiev, A. De Torner, P. Martínez P, P. Mascaró, J. Yaringaño, P. Benito, O. Mirallas, J. Hernando
- PO-55 MIR5683 PREDICTS VENOUS THROMBOEMBOLISM IN ADVANCED GASTRIC CANCER THROUGH REGULATION OF FIBRINOLYSIS AND ENDOTHELIAL TFPI EXPRESSION
D. Zaragoza Huesca, J. Peñas Martínez, R. Teruel, G. Ricote, A. Carmona Bayonas, A. Fernández Montes, P. Jiménez Fonseca, L. Macia Rivas, P. Morales Del Burgo, L. Visa, R. Hernández, E. Martínez De Castro, A. Pereira Elorrieta, M. E. De La Morena Barrio, P. Garrido Rodríguez, M. L. Lozano, C. Martínez, R. González Conejero, I. Martínez Martínez



- PO-56 AAV-MOUSE DNASE I SUSTAINS LONG-TERM DNASE I EXPRESSION IN VIVO AND SUPPRESSES BREAST CANCER METASTASIS
M. Herre, K. Vemuri, J. Cedervall, S. Nissl, F. Saupe, J. Micallef, H. Lindman, C. A. Maguire, G. Tetz, V. Tetz And Ak. Olsson

Poster Session VII: Therapeutic challenges

Chair: Mariasanta Napolitano (Italy)

- PO-57 PERFORMANCE OF ESTABLISHED VTE RISK ASSESSMENT MODELS FOR THE PREDICTION OF ALL-CAUSE MORTALITY IN PATIENTS WITH CANCER – RESULTS FROM A PROSPECTIVE COHORT STUDY
N. Vladoic, C. Englisch, J. Berger, F. Moik, A. Berghoff, M. Preusser, I. Pabinger, C. Ay
- PO-58 PREDICTION OF CORONARY HEART DISEASE RISK IN BLOOD OR MARROW TRANSPLANT SURVIVORS - A BMT SURVIVOR STUDY (BMTSS) REPORT
R. Gangaraju, Q. Meng, L. Hageman, W. Landier, N. Balas, E. Ross, L. Francisco, A. Bosworth, F. Lennie Wong, D. Weisdorf, R. Bhatia, S. Forman, S. Armenian, S. Bhatia
- PO-59 ANTITHROMBOTIC THERAPY DECISION-MAKING IN ADVANCED CANCER: KEY FACILITATORS AND BARRIERS
A. A. Højen, E. Baddeley, M. Edwards, S. Sivell, K. Lifford, C. Font, V. M. Arfuch, N. Coma-auli, I. Mahe, H. Enggaard, M. Søgaaard, F. A. Klok, S. Noble
- PO-60 CLINICIANS' VIEWS AND EXPERIENCES OF ANTITHROMBOTIC THERAPY DECISION MAKING IN ADVANCED CANCER
A. A. Højen, E. Baddeley, M. Edwards, S. Sivell, K. Lifford, C. Font, V. M. Arfuch, N. Coma-auli, I. Mahe, H. Enggaard, M. Søgaaard, F. A. Klok, S. Noble
- PO-61 LONG TERM VENOUS THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS WITH COVID-19 INFECTION
M. Blancarte Ibarra, A. Morales Arteaga, L. Phan, E. Young, C. Rojas Hernandez
- PO-62 CATHETER-RELATED THROMBOSIS VS FIBROBLASTIC SLEEVE. INCIDENCE AND IMPACT IN ONCOLOGICAL AND HEMATOLOGICAL PATIENTS WITH PERIPHERALLY INSERTED CENTRAL CATHETER
M. Nunziata, F. P. Damiano, F. Cannavacciuolo, M. Amitrano, S. Mangiacapra
- PO-63 HEMOSTASIS AND THROMBOSIS CONSULTATIONS AT A CANCER DEDICATED INSTITUTION: A SIX-MONTH EXPERIENCE
C. Rothschild, Aags. Brandão, E. Okazaki, V. Rocha, Pr. Villaça
- PO-64 PATTERNS OF VENOUS THROMBOEMBOLIC EVENTS AND THEIR CLINICAL IMPLICATIONS IN PATIENTS WITH NEUROENDOCRINE NEOPLASMS
M. Roca, S. Serradell, S. Eremiev, B. Alonso, A. García, A. Casteras, P. Martínez, A. De Torner, J. Capdevila, J. Hernando



- PO-65 CANCER-ASSOCIATED THROMBOEMBOLISM (CAT) RISK FACTORS AS WELL AS FRAILTY PREDICT IMMUNOTHERAPY-ASSOCIATED VENOUS THROMBOEMBOLISM (IAT) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
M.A. Cheong, K.M. Sanfilippo, D.C. Calverley, N.M. Kuderer

Poster Session VIII: Biomarkers/Hypercoagulability II

Chair: Francesca Schieppati (Italy)

- PO-66 PLASMA KININOGEN LEVELS PREDICT DEVELOPMENT OF VENOUS THROMBOSIS IN CANCER PATIENTS: ANALYSIS OF SAMPLES FROM THE CASSINI STUDY
A. Khorana, E. Feener, Y. Shim, D. Lee, J. Barnard, K. McCrae
- PO-67 ERYTHROCYTE-RELATED PARAMETERS IN RELATION TO CANCER DIAGNOSIS: A CASE-COHORT STUDY OF HEALTHY SUBJECTS
C.J. Tartari, S. Bolognini, C. Ticozzi, S. Gamba, L. Russo, C. Verzeroli, C. Giaccherini, L. Barcella, M. Marchetti, A. Falanga
- PO-68 NETS BIOMARKERS IN WOMEN WITH ENDOMETRIAL AND CERVICAL CANCER
A. Makatsariya, J. Khizroeva, V. Bitsadze, A. Solopova, A. Vorobev, N. Makatsariya, I. Elalamy, J-c. Gris, M. Tretyakova, E. Slukhanchuk, K. Grigoreva, Z. Aslanova, E. Kudryavtseva, M. Malykh-bakhtina, A. Lazarchuk
- PO-69 MARKERS OF COAGULOPATHY IN MULTIPLE MYELOMA
K. Chasakova, L. Slavik, D. Starostka, J. Ulehlova, T. Papajik, J. Minarik
- PO-70 THROMBUS CHARACTERISTICS (COMPOSITION AND RESPONSE TO IN VITRO THROMBOLYSIS) AND PLASMA BIOMARKERS IN CANCER-RELATED ACUTE ISCHEMIC STROKE
C. Habay, B. Ho-Tin-Noe, I. Arab, L. Kabbaj, M. Mazighi, N. Ajzenberg, J-P. Desilles, D. Faille
- PO-71 CLINICAL SIGNIFICANCE OF IDENTIFYING ADAMTS13 AND VWF AS A HIGH-RISK FACTOR FOR THROMBOSIS IN GYNECOLOGICAL CANCER PATIENTS
V. Bitsadze, A. Vorobev, A. Makatsariya, S. Einullaeva, A. Solopova, J. Khizroeva, A. Shatilina, I. Dikaeva
- PO-72 PLATELET PROTEOMIC PROFILING REVEALS MEDIATORS OF THROMBOSIS AND PROTEOSTASIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
S. Kelliher, S. Gamba, L. Weiss, Z. Shen, M. Marchetti, F. Schieppati, C. Scaife, S. Madden, K. Bennett, A. Fortune, S. Maung, M. Fay, F. Ní Áinle, P. Maguire, A. Falanga, B. Kevane, A. Krishnan
- PO-73 NETOSIS IN GYNECOLOGICAL CANCER PATIENTS DURING ANTITUMOR THERAPY
A. Makatsariya, E. Slukhanchuk, V. Bitsadze, A. Solopova, A. Vorobev, J. Khizroeva, N. Makatsariya, M. Kalashnikova, N. Gashimova, M. Kvaratskhelia, S. Einullaeva, I. Dikaeva
- PO-74 AGEING AS SHARED RISK FACTOR FOR CANCER AND CARDIOVASCULAR DISEASE: THE IMPACT OF CANCER ON VASCULAR REMODELING
F. De Vries, N. Deckers, A. Jaminon, D. Van Der Hove, M. Van Zandvoort, L. Dubois, L. Schurgers